SPRINGFIELD, Mo., Oct. 11 /PRNewswire/ -- Bio-Kinetic Clinical Applications, Inc. (Bio-Kinetic), a leading provider of Phase I clinical study services to the pharmaceutical and biotechnology industry, announced plans to build a new state-of-the-art 108 bed facility on its corporate campus, increasing its total capacity to 240 Phase I beds. The new facility is set to open during the second half of 2006.
Dale Bourg, Chairman and Chief Executive Officer, who founded Bio-Kinetic with Dave Koenigsfeld in 1994, said, "Increasing demand for our services has made it difficult to accommodate all of our valued clients. This additional capacity will allow us to meet current client needs and be prepared for increased demand as well."
Funding for this major expansion along with additional capital to purse other growth opportunities was part of a recently-announced investment by private equity funds managed by The Argentum Group and First Analysis Corporation. Dave Koenigsfeld, Chief Operating Officer, added, "In addition to the new beds, the new facility will also provide much needed office space for clients while they are on-site and will accommodate our growing employee base."
Bio-Kinetic, http://www.bkca.us, is a drug development services company that designs and conducts Phase I clinical studies for branded pharmaceutical, bio-technology, and generic drug companies. The company owns and operates a 132-bed Phase I facility in Springfield, Missouri. It is currently expanding its capacity to 240 beds, which will position Bio-Kinetic as one of the larger independent Phase I facilities in the country. The Company is known for its clinical quality, having developed an outstanding reputation for study designs, recruiting and screening study participants, and collecting and reporting clinical data.
Bio-Kinetic Clinical Applications, Inc.